Document is current
Any future updates will be listed below
-
Authors
Liang, Jackson https://orcid.org/0000-0003-3778-4614
Ong, Christy
Heslop, Kareem
Guan, Jane
Kameswaran, Vasumathi https://orcid.org/0000-0003-2552-6183
Daniel, Bence https://orcid.org/0000-0002-2410-8767
Shi, Minyi
Liang, Yuxin
Giltnane, Jennifer M. https://orcid.org/0000-0002-8333-9995
Aimi, Junko
Chang, Ching-Wei
Gates, Mary R.
Eng-Wong, Jennifer
Perez-Moreno, Pablo
Jhaveri, Komal L. https://orcid.org/0000-0003-0472-1254
Turner, Nicholas C. https://orcid.org/0000-0001-8937-0873
Lim, Elgene https://orcid.org/0000-0001-8065-8838
Metcalfe, Ciara
Moore, Heather M.
- License Information
-
More Information
Article History
Received: 1 April 2025
Accepted: 13 March 2026
First Online: 1 April 2026
Competing interests
: The authors declare the following competing interests: excepting K.L. Jhaveri, N.C. Turner, and E. Lim, all authors are Genentech/Roche employees and own shares of Roche. C.M. is a named co-inventor on patent 11081236 entitled “Diagnostic and therapeutic methods for the treatment of breast cancer”. K.L. Jhaveri has a consultant/advisory board role in Novartis, Pfizer, BMS, Jounce Therapeutics, Taiho Oncology, Genentech, Inc., AbbVie, Eisai, AstraZeneca, Blueprint Medicine, Daiichi Sankyo, Sun Pharma Advanced Research Company Ltd, Gilead, Seattle Genetics, Olema Pharmaceuticals, Menarini/Stemline, and Lilly/Loxo Oncology; and has received research funding from Novartis, Clovis Oncology, Genentech, Inc., AstraZeneca, ADC Therapeutics, Novita Pharmaceuticals, Debio Pharmaceuticals, Pfizer, Lilly Pharmaceuticals/Loxo Oncology, Zymeworks, Gilead, Puma Biotechnology, Context Therapeutics, and Merck Pharmaceuticals. N.C. Turner has received advisory board honoraria from AstraZeneca, Lilly, Pfizer, Roche–Genentech, Novartis, GlaxoSmithKline, Repare Therapeutics, Relay Therapeutics, Zentalis, Gilead, Inivata, Guardant, and Exact Sciences; and research funding from AstraZeneca, Pfizer, Roche–Genentech, Merck Sharpe & Dohme, Guardant Health, Invitae, Inivata, Personalis, and Natera. E. Lim reports research support from Ellipses, Novartis, and Pfizer; speaker compensation from AstraZeneca, Gilead, Novartis, Lilly, Pfizer and Roche; meeting and/or travel support from AstraZeneca, Novartis, and Gilead; advisory board compensation from AstraZeneca, Gilead, Lilly, MSD, Novartis, Pfizer and Roche; and leadership or fiduciary roles in the Breast Cancer Trials and University of New South Wales.
